Alpha radiation seeds target tumors from the inside
NCT ID NCT04534127
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a device called DaRT that delivers a unique type of radiation (alpha particles) directly into tumors. It is designed for people with certain skin cancers, mouth cancers, or soft tissue sarcomas that are accessible for direct injection. The goal is to see if this approach can shrink or control tumors while being safe.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Diffusing Alpha Radiation Emitters Therapy (DaRT) device
What this could lead to
If effective, this approach could offer a new, targeted treatment option for certain skin, mouth, and soft tissue cancers without the need for surgery or systemic therapy.
What could go wrong
This is an early study with a small number of participants, so results may not apply to all patients. The treatment involves inserting radioactive seeds into tumors, which carries risks like infection, pain, or incomplete tumor coverage.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SKIN CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Sharett institute, Hadassah Medical Center - Ein-Kerem
RECRUITINGJerusalem, 91120, Israel
Contact